Biophysics & Medical Physics, Sofia University "St. Kliment Ohridski", 5 James Boucher Blvd., 1164, Sofia, Bulgaria.
Department of Virology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Georgi Bonchev Str., 1113, Sofia, Bulgaria.
Biomed Pharmacother. 2018 Feb;98:29-35. doi: 10.1016/j.biopha.2017.12.014. Epub 2017 Dec 11.
Influenza pathogenesis comprises a complex cascade of impaired cellular processes resulting from the viral replication and exaggerated immune response accompanied by reactive oxygen species (ROS) burst and oxidative stress, destructing membranous structures and tissues. By classical virological and biochemical methods we compared and evaluated the therapeutic effects of 2.5mg/kg/day of the antiviral drug - oseltamivir (OS), 500mg/kg/day of the immune modulator - isoprinosine (IP) and 500mg/kg/day of the antioxidant agent ellagic acid (EA) with a focus on their combined activities in influenza H3N2 virus-infected mice. The survival, lung pathology and titers, as well as the oxidative stress biomarker thiobarbituric acid reactive substances (TBARS) in the lungs, liver and blood plasma, correlated to the activities of the antioxidant enzymes superoxide dismutase (SOD) and glutathione reductase (GR) were assessed. We found that the viral inhibitor applied together with the immune modulator and the antioxidant exhibited strong therapeutic effects on the survival of the influenza-challenged mice. That effect was mostly pronounced for the triple combination - protection index (PI) of 75.2%, mean survival time (MST) extended by 5.8 days compared to the PBS control and significant reduction of the lung titers by 1.38 Δlg; 2.3 scores lower lung pathology and 8 times reduction of the accumulated TBARS in the lungs and liver on the 5 day p.i. The enzymatic assays revealed that this combination demonstrated very good protection against the damaging superoxide radicals (83% efficiency of SOD, in comparison to healthy controls 100%). The double combinations of OS with IP and EA also showed protective effects according to the virological analysis - PI of 53.1% and 54.5%. Ten times higher GR activity was observed when the combination EA+OS and monotherapy of EA were applied (96% in comparison to healthy controls 100%). The best antioxidant effect in blood plasma was observed in the EA+IP group - 4 times reduction in the TBARS-content compared to infected controls but it did not have any efficacy on the survival and lung injury.
流感发病机制包括一系列复杂的细胞过程受损,这些损伤是由病毒复制和过度免疫反应引起的,伴随着活性氧(ROS)爆发和氧化应激,破坏膜结构和组织。我们通过经典的病毒学和生化方法,比较和评估了抗病毒药物奥司他韦(OS)、免疫调节剂异丙肌苷(IP)和抗氧化剂鞣花酸(EA)的治疗效果,剂量分别为 2.5mg/kg/天、500mg/kg/天和 500mg/kg/天,重点研究了它们在感染 H3N2 流感病毒的小鼠中的联合作用。我们评估了存活率、肺部病变和滴度,以及肺部、肝脏和血浆中的氧化应激生物标志物硫代巴比妥酸反应物质(TBARS)与抗氧化酶超氧化物歧化酶(SOD)和谷胱甘肽还原酶(GR)活性的相关性。我们发现,病毒抑制剂与免疫调节剂和抗氧化剂联合使用,对流感病毒感染的小鼠的存活率有很强的治疗作用。对于三重组合,这种效果最为显著,保护指数(PI)为 75.2%,与 PBS 对照组相比,平均存活时间(MST)延长了 5.8 天,肺部滴度降低了 1.38 Δlg,肺部和肝脏中的 TBARS 分别减少了 2.3 分和 8 倍。酶活性分析显示,与健康对照组(100%)相比,该组合对超氧自由基的损伤具有非常好的保护作用(SOD 效率为 83%)。OS 与 IP 和 EA 的双重组合也根据病毒学分析显示出保护作用-PI 为 53.1%和 54.5%。当应用 EA+OS 组合和 EA 单药治疗时,GR 活性增加了 10 倍(与健康对照组相比为 96%)。在 EA+IP 组中观察到最佳的血浆抗氧化效果,与感染对照组相比,TBARS 含量降低了 4 倍,但对存活率和肺损伤没有任何疗效。